§ — Researched for · Sexual & hormonal health
Bremelanotide (PT-141) is FDA-approved for low sexual desire in premenopausal women, with modest trial effects and nausea in about 40% of users. Its use in men is off-label and unproven; melanotan II, often sold for the same purpose, has no approval anywhere.
Reviewed September 2026 · Sources: FDA, EMA
02 — What is being studied
The field is central melanocortin signalling: unlike vascular drugs, these peptides act on receptors in the brain that modulate desire and arousal. The approval pathway for bremelanotide used validated desire and distress instruments in premenopausal women with hypoactive sexual desire disorder, with placebo-controlled trials and pre-specified endpoints.
Outside that indication the evidence stops. Male use is off-label and rests on early or uncontrolled data; postmenopausal women were not part of the registration programme. Melanotan II, a related and unapproved compound, is frequently sold for the same purpose without any trial support and with a documented adverse-event record. Sharing a receptor family is not the same as sharing evidence, and as of September 2026 only one peptide in this group has any.
03 — The table
| Peptide | Researched for | Evidence | Regulatory status | As of |
|---|---|---|---|---|
| PT-141 | Hypoactive sexual desire disorder in women; erectile dysfunction in men (earlier programs). | A | FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Use in men or for other purposes is off-label. | 2026-09-06 |
| Melanotan II | Skin tanning, erectile dysfunction (abandoned development). | D | Not FDA-approved; FDA has issued consumer warnings. Previously withdrawn from review; FDA has announced a further PCAC meeting before the end of February 2027 to reconsider it. | 2026-09-06 |
04 — Per peptide
Regulatory status · United States · as of September 2026
FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Use in men or for other purposes is off-label.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forHypoactive sexual desire disorder in women; erectile dysfunction in men (earlier programs).
Full profile: PT-141 →Regulatory status · United States · as of September 2026
Not FDA-approved; FDA has issued consumer warnings. Previously withdrawn from review; FDA has announced a further PCAC meeting before the end of February 2027 to reconsider it.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Researched forSkin tanning, erectile dysfunction (abandoned development).
Full profile: Melanotan II →05 — What the data does not show
A reliable effect in men, benefit in postmenopausal women and any performance enhancement have not been shown.
06 — Questions for your physician
Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.
Reviewed September 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.